Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial.

Glass, Bertram

Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. [electronic resource] - The Lancet. Oncology Jun 2014 - 757-66 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1474-5488

10.1016/S1470-2045(14)70161-5 doi


Adult
Antibodies, Monoclonal, Murine-Derived--adverse effects
Combined Modality Therapy
Female
Graft vs Host Disease--etiology
Hematopoietic Stem Cell Transplantation--adverse effects
Humans
Lymphoma, Non-Hodgkin--mortality
Male
Middle Aged
Recurrence
Rituximab
Transplantation Conditioning
Transplantation, Homologous